Maravai LifeSciences Holdings, Inc. appointed Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde, who will assist during the transition until January 31, 2026. Asarpota's compensation includes a $550,000 salary, a $200,000 sign-on bonus, and equity awards valued significantly in stock options and units.